ALSO NOTED: Novartis plots $700M biotech plant; Genzyme wins marketing approval; Glenmark, Forest to pursue Phase II; and much

> Novartis will plow $700 million into a new cell-culturing facility in Singapore. The plant will boost the drug maker's capacity for biotech drugs, delivering products for commercial distribution and for clinical development. Report

> Genzyme has won FDA marketing approval for Epicel, a therapy for severe burns. Release

> Researchers at Glenmark Pharmaceuticals and Forest Laboratories have been given a partial favorable response for an additional mid-stage study of GRC 3886 for asthma and COPD. Report

> Warburg Pincus has wrapped its $3.67 billion buyout of Bausch & Lomb. Release

> Shares of Dusa Pharmaceuticals surged this morning on the news that it had settled a patent dispute with River's Edge Pharmaceuticals regarding Nicomide. Report

> Look for a crackdown on direct-to-consumer ads if John Edwards is elected in 2008. Report

> You win some, you lose some. Bayer is abandoning plans to launch a bigger dose of its multiple sclerosis treatment Betaferon. Report

> Outgoing GlaxoSmithKline CEO Jean-Paul Garnier is shouldering the heavy load of layoffs and restructuring to give his successor Andrew Witty a clean slate when he takes over next May, the Times of London is reporting. Report

And Finally... Scientists from Bangor University have found a 400-year-old clam, the oldest living animal known to science. Report